Clene Inc.
CLNN
Rank in Stocks
#21810
Clene Inc. is a biopharmaceutical firm in the clinical development phase,... Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Share Price
$4.38
Last synced: 2026-11-09
Market Cap
$62.26M
Change (1 day)
10.89%
Change (1 year)
-54.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Clene Inc. (CLNN)
Category
Healthcare
Operating Margin for Clene Inc. (CLNN)
Operating Margin as of November 2026 TTM: -10,304.57%
According to Clene Inc.'s latest financial reports, its current operating margin (TTM) is -10,304.57%. At the end of 2025 the company had an operating margin of -11,541.50%.
Operating Margin history for Clene Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -10,304.57% | -10.72% |
| 2025 | -11,541.50% | 19.28% |
| 2024 | -9,676.32% | 56.10% |
| 2023 | -6,198.78% | -39.43% |
| 2022 | -10,234.46% | 48.06% |
| 2021 | -6,912.59% | -29.55% |
| 2020 | -9,812.62% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Clene Inc.'s operating margin
What is Clene Inc.'s operating margin?
Clene Inc.'s operating margin is -10,304.57%, as of Nov 2026.
What was Clene Inc.'s operating margin in 2025?
In 2025, Clene Inc.'s operating margin was -11,541.50%, compared with -9,676.32% in 2024.
How has Clene Inc.'s operating margin changed since 2020?
From 2020 to 2025, Clene Inc.'s operating margin was highest in 2023 (-6,198.78%) and lowest in 2025 (-11,541.50%).
How does Clene Inc.'s operating margin compare with similar companies?
Clene Inc.'s operating margin (-10,304.57%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.